Understanding Multidrug Resistance In Cancer: Identification Of The Substrate And Inhibitor Binding Sites In P-glycoprotein
Funder
National Health and Medical Research Council
Funding Amount
$284,343.00
Summary
Cancers expressing the multidrug transporter P-glycoprotein (P-gp) are resistant to chemotherapy. The clinical impact of P-gp is so large that the National Cancer Institute (USA) “profiles” all anticancer drugs for transport by P-gp, primarily because the mechanism of drug binding and transport by P-gp is unknown. The aim of this proposal is to understand the molecular details of how drugs bind to and interact with P-gp, a major step in our understanding of P-gp mediated chemotherapy resistance.
How Do Anaesthetics Work? A Rational Basis For Safer General Anaesthesia.
Funder
National Health and Medical Research Council
Funding Amount
$592,008.00
Summary
General anaesthetics are a mainstay of modern medicine, but have a small safety margin, requiring skilled anaesthetists for their safe use. There is growing evidence that general anaesthetic exposure may have long-term effects on brain function in both newborns and the elderly. This project will provide a detailed molecular description of anaesthetic action and specificity. It will provide the basis for designing new anaesthetics that are safer, both immediately and for long-term brain function.
Structural Biology Of Bacterial Lipid II-glycopeptide Antibiotic Interactions
Funder
National Health and Medical Research Council
Funding Amount
$605,190.00
Summary
Drug resistant bacteria are threatening our ability to successfully treat serious life-endangering infections, with many common antibiotics no longer effective. We will study in atomic detail how one class of antibiotics interacts with bacteria in order to design new members of this group that can overcome resistance.
Optimization Of Splice Switching Therapies To Treat Duchenne Muscular Dystrophy
Funder
National Health and Medical Research Council
Funding Amount
$448,827.00
Summary
Duchenne muscular dystrophy, the most common and serious form of childhood muscle wasting, is caused by mutations in the dystrophin gene that block synthesis of the normal product. Antisense oligomers have been used in clinical trials to remove the disease-causing part of the message and rescue expression. Clinical trials have demonstrated proof-of-concept, although individual responses varied. This application seeks to improve the therapeutic potential of these compounds.